Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 28, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

High-risk multiple myeloma: does it still exist?

Sascha A Tuchman1, Sagar Lonial

  • 1Division of Medical Oncology, Department of Medicine, Duke University Medical Center, Durham, NC, USA.

Clinical Lymphoma, Myeloma & Leukemia
|November 1, 2011
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Idecabtagene vicleucel and endogenous T-cell phenotypes linked to progression-free survival in relapsed multiple myeloma.

HemaSphere·2026
Same author

High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same author

Spatial multi-omics of multiple myeloma uncovers niche-dependent pro-myeloma and immunosuppressive signaling in the bone marrow and extramedullary lesions.

bioRxiv : the preprint server for biology·2026
Same author

The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody-Drug Conjugates for the Treatment of Multiple Myeloma.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Diagnostic Journeys and Delays in AL Amyloidosis: Insights From a Cross-Sectional Patient Survey.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Treatment Initiation Among Black and White Older Adults With Multiple Myeloma: A SEER-Medicare Analysis.

Cancer medicine·2026
Same journal

Myelodysplastic Syndrome With Autoimmune Disease: Clinical and Molecular Features and Survival Outcomes.

Clinical lymphoma, myeloma & leukemia·2026
Same journal

The Prognostic Role of Interim [18F]FDG PET/CT in Diffuse Large B-Cell Lymphoma: An Updated Systematic Review and Meta-analysis.

Clinical lymphoma, myeloma & leukemia·2026
Same journal

Real-World Evidence of Immunotherapy Sequencing in Multiple Myeloma: Durable Responses With BCMA-Targeting Bispecific Antibodies Following Prior GPRC5D-Targeting Therapy.

Clinical lymphoma, myeloma & leukemia·2026
Same journal

Clinical and Biological Implications of TP53 Abnormalities in Relapsed/Refractory Multiple Myeloma: The DEDALO Study.

Clinical lymphoma, myeloma & leukemia·2026
Same journal

Results of Third-Line Therapy in Philadelphia Chromosome-Positive Adult Acute Lymphoblastic Leukemia.

Clinical lymphoma, myeloma & leukemia·2026
Same journal

Potential Benefits and Harms of Screening Strategies for Monoclonal Gammopathy of Undetermined Significance in the US: A Simulation Study.

Clinical lymphoma, myeloma & leukemia·2026
See all related articles

Recent advances in multiple myeloma (MM) treatments offer improved survival. Novel therapies may personalize treatment for high-risk MM, but more clinical trials are needed to confirm effectiveness.

Area of Science:

  • Hematology
  • Oncology
  • Clinical Therapeutics

Background:

  • Multiple myeloma (MM) treatment has evolved significantly, from early combinations to stem cell transplants and novel agents.
  • Historically, MM therapy was standardized, lacking personalization based on molecular subtypes.
  • Recent novel therapies have improved survival across MM patient populations.

Purpose of the Study:

  • To review treatment milestones in multiple myeloma (MM).
  • To explore the potential of novel agents in personalizing MM therapy.
  • To highlight the need for prospective data and clinical trials for individualized MM care.

Main Methods:

  • Literature review of historical and recent advancements in multiple myeloma treatment.
  • Analysis of the impact of novel agents on survival and prognostic factors.

Related Experiment Videos

Last Updated: May 28, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

  • Discussion of the transition towards individualized therapy in MM.

    • Main Results:

    • Novel therapies have extended survival for MM patients.
    • Emerging data suggest novel agents can mitigate risks associated with high-risk MM.
    • These findings indicate potential for personalized treatment strategies.

    Conclusions:

    • Novel therapies represent a shift towards individualized multiple myeloma treatment.
    • Prospective data are crucial to validate personalized approaches.
    • Multi-institutional clinical trials are necessary to redefine MM care standards.